A new study found a link between NovoNordisk’s blockbuster drug Ozempic and a reduced risk of Alzheimer’s disease. 23andMe, ...

The UK’s AstraZeneca, which is working on an oral GLP-1, also views the drugs as part of a combination strategy. In other ...

Participants were survivors of acute ischemic strokes likely related to their Afib. In the hospital stroke unit, they were ...

Last week, U.S. consumer groups and labour unions petitioned the U.S. Federal Trade Commission to block Novo Holdings, the ...

A WhatsApp message has earned Moderna a reprimand from the UK's Prescription Medicines Code of Practice Authority (PMCPA), ...

Economic data in Q3 indicated lower inflation and employment, prompting the Fed to cut interest rates by 50bps, influencing ...

This week, Roche RHHBY announced its third-quarter and nine-month results. Sanofi SNY confirmed that it is holding exclusive ...

Sanofi and CD&R entered into exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella.

NUPCO signs over 15 new MoUs at the Global Health Exhibition 2024, deepening its ties with the private sector and advancing ...

Karan Johar's noticeable weight loss has sparked rumours about his possible use of Ozempic, a diabetes drug known for its ...

Market volatility in Q3 was driven by softer-than-expected US employment data, but resilient earnings and rate cuts led to a ...

GLP-1 drugs like Wegovy (NVO) might help with weight loss, but they aren’t leading to lower health care costs yet, according to a new analysis of U.S. health insurance claims.